Evidence map›Paper›PMID 39457650›Full record

ArticleBiomedicines2024

Association of Senescence Markers with Age and Allograft Rejection in Renal Transplant Recipients.

Peter Vavrinec, Jakub Krivy, Sona Sykorova, Helena Bandzuchova, Zuzana Zilinska, Diana Vavrincova-Yaghi

Abstract read
In one paragraph

Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Peter VavrinecDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University in Bratislava, 832 32 Bratislava, Slovakia.
Jakub KrivyDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University in Bratislava, 832 32 Bratislava, Slovakia.
Sona SykorovaDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University in Bratislava, 832 32 Bratislava, Slovakia.
Helena BandzuchovaNational Transplant Organization, 833 03 Bratislava, Slovakia.
Zuzana ZilinskaDepartment of Nephrology and Kidney Transplantations, University Hospital and Comenius University in Bratislava, 833 05 Bratislava, Slovakia.
Diana Vavrincova-YaghiDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University in Bratislava, 832 32 Bratislava, Slovakia.ORCID 0000-0002-6608-1742

Funding

Slovak Grant Agency VEGA 1/0121/22Slovak Grant Agency VEGA 1/0513/24Slovak Research and Development Agency APVV-23-0399
6 · The paper itself

Abstract

BACKGROUND/

objectivesRenal transplantation is the treatment of choice for patients with end-stage renal disease. In the last decade, the number of older renal transplant recipients has significantly increased. However, these patients are at a higher risk of developing post-transplant complications. Therefore, identifying the suitable biomarkers to predict which older patients are at risk of complications is crucial. Cellular senescence could provide insights into the increased vulnerability in this population and guide personalized post-transplant care.

methodsThis preliminary study involved biopsies from 25 patients with renal allograft rejection and 18 patients without rejection, further divided into older (50-65 years) and younger (29-40 years) groups. Biopsies were collected at different time points after transplantation, and rejection was classified according to the histological Banff 07 criteria. Additionally, immunohistochemistry for the markers of cellular senescence, p27

resultsWe observed that the number of p27

conclusionsOur preliminary data suggest the strong potential of both p16

Indexed as

ageallograft rejectionkidney transplantationp16INK4ap27kip1senescence

Identifiers

PMID39457650
PMCPMC11505218

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.